Palucorcel - Janssen Biotech

Drug Profile

Palucorcel - Janssen Biotech

Alternative Names: CNTO-2476

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Developer Centocor Ortho Biotech; Janssen Biotech
  • Class Eye disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration
  • No development reported Retinitis pigmentosa

Most Recent Events

  • 13 Nov 2017 Janssen Pharmaceutical withdrawn a phase II trial for Age-related macular degeneration (In adults, In the elderly) in Japan, prior to enrolment (Ophthalmic) (NCT02895815) (JapicCTI163414)
  • 31 May 2017 Janssen Pharmaceuticals completes a phase I/II trial in Age-related macular degeneration in USA(Ophthalmic) (NCT01226628)
  • 06 Sep 2016 Janssen Pharmaceutical plans a phase II trial for Age-related macular degeneration (In adults, In the elderly) in Japan (Ophthalmic) (NCT02895815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top